Umbilical Mesenchymal Stem Cells and Mononuclear Cells Infusion in Type 1 Diabetes Mellitus
Status:
Unknown status
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
Umbilical mesenchymal stem cells (UC-MSCs) infusion is supposed be a promising regeneration
therapy with mild side effect as indicated by large quantities of animal experiments and some
clinical trials. There are few UC-MSCs clinical trials with regard to diabetes mellitus. The
investigators hypothesize that infusion of USC-MSCs may provide multiple signals for
beta-cell regeneration and even re-differentiate into local tissues in diabetes mellitus
patients, resulting in improvement of diabetic control, of which the effect may be promoted
by concomitant infusion of bone marrow mononuclear cells and maximized by intra-arterial
pancreatic infusion through angiography.